US Stock MarketDetailed Quotes

ADAP Adaptimmune Therapeutics

Watchlist
  • 0.699
  • -0.025-3.40%
Trading Dec 3 13:04 ET
178.76MMarket Cap-4183P/E (TTM)

Adaptimmune Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
(FY)Dec 31, 2022
(Q4)Dec 31, 2022
Total revenue
458.83%40.9M
2,399.63%128.23M
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
Operating revenue
458.83%40.9M
2,399.63%128.23M
-88.07%5.68M
122.05%60.28M
-97.91%231K
4.45%7.32M
-7.37%5.13M
1,231.50%47.6M
341.50%27.15M
678.26%11.03M
Cost of revenue
Gross profit
Operating expense
3.02%55.58M
18.97%59.53M
24.18%54.94M
5.03%198.32M
39.23%50.09M
7.91%53.95M
1.52%50.04M
-17.39%44.24M
12.13%188.82M
-18.76%35.97M
Selling and administrative expenses
31.63%21.28M
-4.93%19.08M
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
-General and administrative expense
31.63%21.28M
-4.93%19.08M
5.55%19.73M
17.55%71.81M
30.63%16.88M
-3.87%16.16M
37.96%20.07M
11.25%18.69M
6.61%61.09M
-12.55%12.92M
Research and development costs
-9.22%34.3M
34.98%40.45M
37.81%35.21M
-0.95%126.51M
44.06%33.21M
13.88%37.79M
-13.74%29.97M
-30.49%25.55M
14.98%127.73M
-21.87%23.05M
Operating profit
68.52%-14.68M
252.98%68.7M
-1,566.54%-49.26M
14.62%-138.04M
-99.86%-49.86M
-8.47%-46.63M
-2.64%-44.91M
106.72%3.36M
0.36%-161.67M
41.80%-24.95M
Net non-operating interest income expense
-54.07%987K
-44.91%850K
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
Non-operating interest income
-2.47%2.1M
-10.82%1.38M
98.96%1.35M
286.77%5.96M
205.16%1.6M
563.27%2.15M
332.21%1.54M
100.00%676K
40.82%1.54M
192.18%523K
Non-operating interest expense
--1.11M
--526K
----
----
----
--0
--0
----
----
----
Other net income (expense)
-619.30%-3.09M
-97.81%497K
97.43%-61K
789.69%19.54M
91.84%-313K
-126.16%-430K
3,558.93%22.66M
-19,883.33%-2.37M
-173.55%-2.83M
-195.00%-3.83M
Special income (charges)
--0
--0
--0
985.76%20.35M
--0
---106K
--22.16M
---1.7M
---2.3M
---2.3M
-Less：Restructuring and merger&acquisition
--0
--0
--0
-985.76%-20.35M
--0
--106K
---22.16M
--1.7M
--2.3M
--2.3M
Other non- operating income (expenses)
-854.63%-3.09M
-0.80%497K
90.91%-61K
-50.56%-807K
79.64%-313K
-119.71%-324K
176.49%501K
-5,691.67%-671K
-113.91%-536K
-138.08%-1.54M
Income before tax
62.63%-16.79M
438.24%70.05M
-2,988.44%-47.98M
30.94%-112.54M
-71.90%-48.57M
-9.49%-44.91M
52.99%-20.71M
103.35%1.66M
-3.60%-162.96M
26.89%-28.26M
Income tax
20.96%831K
-22.65%526K
-15.84%526K
-46.50%1.34M
-166.00%-656K
72.18%687K
44.68%680K
-1.42%625K
215.68%2.5M
375.60%994K
Net income
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Net income continuous Operations
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Minority interest income
Net income attributable to the parent company
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
61.37%-17.62M
425.03%69.52M
-4,781.76%-48.5M
31.18%-113.87M
-63.82%-47.92M
-10.09%-45.6M
51.96%-21.39M
102.06%1.04M
-4.66%-165.46M
24.73%-29.25M
Basic earnings per share
66.67%-0.06
350.00%0.3
-2,970.81%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.09%0.0063
0.00%-1.02
25.00%-0.18
Diluted earnings per share
66.67%-0.06
300.00%0.24
-2,996.68%-0.18
47.06%-0.54
0.00%-0.18
25.00%-0.18
60.00%-0.12
102.07%0.0062
0.00%-1.02
25.00%-0.18
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
(Q3)Sep 30, 2024 (Q2)Jun 30, 2024 (Q1)Mar 31, 2024 (FY)Dec 31, 2023 (Q4)Dec 31, 2023 (Q3)Sep 30, 2023 (Q2)Jun 30, 2023 (Q1)Mar 31, 2023 (FY)Dec 31, 2022 (Q4)Dec 31, 2022
Total revenue 458.83%40.9M 2,399.63%128.23M -88.07%5.68M 122.05%60.28M -97.91%231K 4.45%7.32M -7.37%5.13M 1,231.50%47.6M 341.50%27.15M 678.26%11.03M
Operating revenue 458.83%40.9M 2,399.63%128.23M -88.07%5.68M 122.05%60.28M -97.91%231K 4.45%7.32M -7.37%5.13M 1,231.50%47.6M 341.50%27.15M 678.26%11.03M
Cost of revenue
Gross profit
Operating expense 3.02%55.58M 18.97%59.53M 24.18%54.94M 5.03%198.32M 39.23%50.09M 7.91%53.95M 1.52%50.04M -17.39%44.24M 12.13%188.82M -18.76%35.97M
Selling and administrative expenses 31.63%21.28M -4.93%19.08M 5.55%19.73M 17.55%71.81M 30.63%16.88M -3.87%16.16M 37.96%20.07M 11.25%18.69M 6.61%61.09M -12.55%12.92M
-General and administrative expense 31.63%21.28M -4.93%19.08M 5.55%19.73M 17.55%71.81M 30.63%16.88M -3.87%16.16M 37.96%20.07M 11.25%18.69M 6.61%61.09M -12.55%12.92M
Research and development costs -9.22%34.3M 34.98%40.45M 37.81%35.21M -0.95%126.51M 44.06%33.21M 13.88%37.79M -13.74%29.97M -30.49%25.55M 14.98%127.73M -21.87%23.05M
Operating profit 68.52%-14.68M 252.98%68.7M -1,566.54%-49.26M 14.62%-138.04M -99.86%-49.86M -8.47%-46.63M -2.64%-44.91M 106.72%3.36M 0.36%-161.67M 41.80%-24.95M
Net non-operating interest income expense -54.07%987K -44.91%850K 98.96%1.35M 286.77%5.96M 205.16%1.6M 563.27%2.15M 332.21%1.54M 100.00%676K 40.82%1.54M 192.18%523K
Non-operating interest income -2.47%2.1M -10.82%1.38M 98.96%1.35M 286.77%5.96M 205.16%1.6M 563.27%2.15M 332.21%1.54M 100.00%676K 40.82%1.54M 192.18%523K
Non-operating interest expense --1.11M --526K ---- ---- ---- --0 --0 ---- ---- ----
Other net income (expense) -619.30%-3.09M -97.81%497K 97.43%-61K 789.69%19.54M 91.84%-313K -126.16%-430K 3,558.93%22.66M -19,883.33%-2.37M -173.55%-2.83M -195.00%-3.83M
Special income (charges) --0 --0 --0 985.76%20.35M --0 ---106K --22.16M ---1.7M ---2.3M ---2.3M
-Less：Restructuring and merger&acquisition --0 --0 --0 -985.76%-20.35M --0 --106K ---22.16M --1.7M --2.3M --2.3M
Other non- operating income (expenses) -854.63%-3.09M -0.80%497K 90.91%-61K -50.56%-807K 79.64%-313K -119.71%-324K 176.49%501K -5,691.67%-671K -113.91%-536K -138.08%-1.54M
Income before tax 62.63%-16.79M 438.24%70.05M -2,988.44%-47.98M 30.94%-112.54M -71.90%-48.57M -9.49%-44.91M 52.99%-20.71M 103.35%1.66M -3.60%-162.96M 26.89%-28.26M
Income tax 20.96%831K -22.65%526K -15.84%526K -46.50%1.34M -166.00%-656K 72.18%687K 44.68%680K -1.42%625K 215.68%2.5M 375.60%994K
Net income 61.37%-17.62M 425.03%69.52M -4,781.76%-48.5M 31.18%-113.87M -63.82%-47.92M -10.09%-45.6M 51.96%-21.39M 102.06%1.04M -4.66%-165.46M 24.73%-29.25M
Net income continuous Operations 61.37%-17.62M 425.03%69.52M -4,781.76%-48.5M 31.18%-113.87M -63.82%-47.92M -10.09%-45.6M 51.96%-21.39M 102.06%1.04M -4.66%-165.46M 24.73%-29.25M
Minority interest income
Net income attributable to the parent company 61.37%-17.62M 425.03%69.52M -4,781.76%-48.5M 31.18%-113.87M -63.82%-47.92M -10.09%-45.6M 51.96%-21.39M 102.06%1.04M -4.66%-165.46M 24.73%-29.25M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 61.37%-17.62M 425.03%69.52M -4,781.76%-48.5M 31.18%-113.87M -63.82%-47.92M -10.09%-45.6M 51.96%-21.39M 102.06%1.04M -4.66%-165.46M 24.73%-29.25M
Basic earnings per share 66.67%-0.06 350.00%0.3 -2,970.81%-0.18 47.06%-0.54 0.00%-0.18 25.00%-0.18 60.00%-0.12 102.09%0.0063 0.00%-1.02 25.00%-0.18
Diluted earnings per share 66.67%-0.06 300.00%0.24 -2,996.68%-0.18 47.06%-0.54 0.00%-0.18 25.00%-0.18 60.00%-0.12 102.07%0.0062 0.00%-1.02 25.00%-0.18
Dividend per share
Currency Unit USD USD USD USD USD USD USD USD USD USD
Accounting Standards US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP US-GAAP
Audit Opinions -- -- -- Unqualified Opinion -- -- -- -- Unqualified Opinion --
Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme CAR-T Therapy
CAR-T Therapy
Intraday-0.16%